Inclusion Criteria:

- Advanced RCC or a resectable renal tumor and at least one measurable inoperable
metastasis (at least 1 cm), in whom anti-angiogenic therapy is indicated

- Patients without target lesions, with bone metastasis

- Histologically confirmed clear cells RCC and possibility of adequate tumor sampling
prior to treatment

- No prior systemic treatment for RCC

- Male or female, at least 18 years

- PS ECOG 0-1

- Life expectancy at least 3 months

- Adequate organ function with the following criteria:

- Total serum bilirubin equal or less than 2 x ULN (Gilbert's disease exempted)

- Serum transaminases and alkaline phosphatases equal or less than 2.5 x ULN, or
in case of liver or bone metastasis equal or less than 5x ULN

- Serum creatinine equal or less than 2 x ULN, creatinine clearance at least 50
ml/min

- Absolute neutrophil count (ANC) at least 1500/mm3

- Platelets at least 100,000/mm3

- Hemoglobin at least 10.0 g/dL

- INR equal or less than 1.7 or prothrombin time (PT) equal or less than 6 sec

- Blood glucose less than 1.5x ULN

- Fasting cholesterol equal or less than 5 mmol/L, triglycerides equal or less
than 200 mg/dl,

- Negative pregnancy test within 7 days prior to enrollment

- Signed and dated IRB/ICE-approved informed consent form

- Willingness and ability to comply with scheduled visits, treatment plans, laboratory
tests and other study procedures.

- Patient covered by the national health system

Exclusion Criteria:

- Previous nephrectomy

- Histology: any histologic type different than ccRCC

- Treatment in a clinical trial in the last 30 days

- Previous treatment with everolimus or other mTOR-inhibitors and anti-angiogenic drugs

- Any of the following within 12 months prior to treatment initiation: severe/unstable
angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive
heart failure, ischemic or hemorrhagic stroke including transient ischemic attack,
abnormal lung function.

- Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic
pressure >90 mmHg, despite optimal medical treatment

- Abnormal ECG (Clinically significant)

- Treatment with vitamin K antagonists. Ongoing treatment with therapeutic doses of
coumarin derivative anticoagulants (e.g. warfarin) or treatment within the 2 weeks
before the first day of everolimus administration. Prophylaxis with low dose warfarin
for deep vein thrombosis is permitted (up to 2 mg/day). Low molecular weight heparin
is allowed.

- Brain metastasis. (Brain scan or MRI is mandatory). Note: Previous treated brain
metastasis (surgery ± radiotherapy, radiotherapy, radiosurgery or gammaknife) and
satisfying the following three criteria are allowed:

- Asymptomatic;

- No evidence of any active brain metastasis 3 months prior inclusion;

- No necessity of corticoid or antiepileptic treatment.

- Pregnancy or breastfeeding.

- Any second malignancy within the last 3 years with the exception of basal cell
carcinoma, in situ cervical cancer and pT1/a bladder cancer with no evidence of
recurrent disease for 12 months.

- Clinically significant gastrointestinal abnormalities including but not limited to:

- Malabsorption syndrome

- Major resection of the stomach or small bowel that could affect the absorption
of the study drug

- Active peptic ulcer disease

- Inflammatory bowel disease

- Ulcerative colitis or other gastrointestinal conditions with increased risk of
perforation

- History of abdominal fistula, gastrointestinal perforation, or intra abdominal
abscess within 28 days prior to beginning study treatment

- Hepatitis B/C

- Hypersensitivity to everolimus or any excipient of everolimus.

- Any active (acute or chronic) or uncontrolled infection/disorders that impair the
ability to evaluate the patient or for the patient to complete the study.